BRPI0407091A - Derivados de uréia cìclica, o respectivo preparo e a respectiva utilização farmacêutica como inibidores de quinases - Google Patents

Derivados de uréia cìclica, o respectivo preparo e a respectiva utilização farmacêutica como inibidores de quinases

Info

Publication number
BRPI0407091A
BRPI0407091A BR0407091-7A BRPI0407091A BRPI0407091A BR PI0407091 A BRPI0407091 A BR PI0407091A BR PI0407091 A BRPI0407091 A BR PI0407091A BR PI0407091 A BRPI0407091 A BR PI0407091A
Authority
BR
Brazil
Prior art keywords
nr5r6
cycloalkyl
alkyl
alkenyl
notably
Prior art date
Application number
BR0407091-7A
Other languages
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0407091A publication Critical patent/BRPI0407091A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

"DERIVADOS DE URéIA CìCLICA, O RESPECTIVO PREPARO E A RESPECTIVA UTILIZAçãO FARMACêUTICA COMO INIBIDORES DE QUINASES". A invenção se refere aos novos produtos de fórmula (1), na qual p representa O a 2, R e R1 representam O ou NH, R2 e R3 representam notadamente hidrogênio, alquila, alquenila, alquinila, cicloalquila, arila e heteroarila ou R2 e R3 formam juntos com o átomo de carbono aos quais estão ligados um radical carbocíclico ou heterocíclico, todos esses radicais sendo eventualmente substituídos, A1 representa simples ligação, alquila, alila, alila e propionila, Y e Y1 representam notadamente H, OCF3, S(O)nCF3, -S(O)n-alq, -SO2CHF2, SO2CF2CF3, -SO2NH2, -S-CF2-CF2-CF3, -OCF2-CH2, -O-CH2-CF3, SF5 e SO2NR5R6 com R5 e R6 escolhidos notadamente dentre hidrogênio, alquila, alquenila, cicloalquila, cicloalquenil, heterocicloalquila, arila e heteroarila eventualmente substituídos ou R5 e R6 formam com N ao qual são ligados um radical heterocíclico, A2 representa A1, CO e SO2, B2 representa um radical heterocíclico eventualmente substituídos por um ou vários substituintes escolhidos dentre os valores de Y2, Y2 representa notadamente hidrogênio, halogênio, hidroxila, ciano, alquila, alcóxi, cicloalquila, heterocicloalquila, arila, heteroarila, -O-alquenila, -Oalquinila, O-cicloalquila, S(O)n-alquila, -S(O)n-alquenila, -S(O)n-alquinila, S(O)n-cicloalquila, -COOR13, -OCOR13, NR5R6, CONR5R6, S(O)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, todos esses radicais sendo eventualmente substituídos, n representa um inteiro de O a 2, esses produtos estando sob todas formas isómeras e os sais, a título de medicamentos.
BR0407091-7A 2003-01-31 2004-01-28 Derivados de uréia cìclica, o respectivo preparo e a respectiva utilização farmacêutica como inibidores de quinases BRPI0407091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
BRPI0407091A true BRPI0407091A (pt) 2006-01-24

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407091-7A BRPI0407091A (pt) 2003-01-31 2004-01-28 Derivados de uréia cìclica, o respectivo preparo e a respectiva utilização farmacêutica como inibidores de quinases

Country Status (24)

Country Link
EP (1) EP1599464B1 (pt)
JP (1) JP4604020B2 (pt)
KR (1) KR20050098286A (pt)
CN (1) CN1768054A (pt)
AR (1) AR042936A1 (pt)
AT (1) ATE482207T1 (pt)
AU (1) AU2004209319A1 (pt)
BR (1) BRPI0407091A (pt)
CA (1) CA2513631A1 (pt)
DE (1) DE602004029236D1 (pt)
FR (1) FR2850652B1 (pt)
HR (1) HRP20050679A2 (pt)
MA (1) MA27651A1 (pt)
ME (1) MEP22608A (pt)
MX (1) MXPA05007407A (pt)
NO (1) NO20054006L (pt)
NZ (1) NZ541270A (pt)
PE (1) PE20040808A1 (pt)
PL (1) PL377811A1 (pt)
RS (1) RS20050657A (pt)
RU (1) RU2341523C2 (pt)
TW (1) TW200505898A (pt)
WO (1) WO2004070050A2 (pt)
ZA (1) ZA200505934B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077344A2 (en) 2003-08-29 2005-08-25 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2535179T3 (es) 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK2368550T3 (da) * 2006-03-27 2013-09-30 Univ California Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
EP2439196A1 (en) 2006-03-29 2012-04-11 The Regents of The University of California Diarylthiohydantoin compounds for use in a method for the treatment of a hyperproliferative disorder
RU2009108280A (ru) 2006-08-08 2010-09-20 Санофи-Авентис (Fr) Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение
US8093254B2 (en) 2006-12-12 2012-01-10 Schering Corporation Aspartyl protease inhibitors
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
WO2010075561A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
SG10201501202TA (en) 2010-02-16 2015-04-29 Aragon Pharmaceuticals Inc Androgen Receptor Modulators And Uses Thereof
EP2655428B1 (en) * 2010-12-21 2022-09-14 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
GEP20196983B (en) 2014-01-14 2019-06-25 Millennium Pharm Inc Heteroaryls and uses thereof
SG11201704764PA (en) 2014-12-11 2017-07-28 Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
KR102559539B1 (ko) * 2016-07-20 2023-07-26 노파르티스 아게 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
RU2763346C2 (ru) * 2017-10-31 2021-12-28 Пелемед Ко., Лтд. Фармацевтическая композиция для предупреждения или лечения острого миелоидного лейкоза или метастатического рака молочной железы

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
AU6541898A (en) * 1997-03-03 1998-09-22 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
WO2001092253A2 (en) * 2000-05-31 2001-12-06 Tanabe Seiyaku Co., Ltd. Inhibitors of alpha l beta 2 mediated cell adhesion
US7476685B2 (en) * 2002-05-16 2009-01-13 Merial Limited Pyridine carboxamide derivatives and their use as pesticides

Also Published As

Publication number Publication date
ATE482207T1 (de) 2010-10-15
RU2005127335A (ru) 2006-09-10
FR2850652A1 (fr) 2004-08-06
NO20054006L (no) 2005-10-13
CN1768054A (zh) 2006-05-03
PL377811A1 (pl) 2006-02-20
KR20050098286A (ko) 2005-10-11
JP2006517569A (ja) 2006-07-27
FR2850652B1 (fr) 2008-05-30
MXPA05007407A (es) 2005-09-12
WO2004070050A3 (fr) 2005-02-17
DE602004029236D1 (de) 2010-11-04
HRP20050679A2 (en) 2006-12-31
JP4604020B2 (ja) 2010-12-22
NO20054006D0 (no) 2005-08-29
WO2004070050A2 (fr) 2004-08-19
AU2004209319A1 (en) 2004-08-19
MA27651A1 (fr) 2005-12-01
RU2341523C2 (ru) 2008-12-20
MEP22608A (en) 2010-06-10
RS20050657A (en) 2007-06-04
EP1599464A2 (fr) 2005-11-30
CA2513631A1 (fr) 2004-08-19
TW200505898A (en) 2005-02-16
EP1599464B1 (fr) 2010-09-22
AR042936A1 (es) 2005-07-06
NZ541270A (en) 2008-11-28
ZA200505934B (en) 2007-06-27
PE20040808A1 (es) 2004-12-31

Similar Documents

Publication Publication Date Title
BRPI0407091A (pt) Derivados de uréia cìclica, o respectivo preparo e a respectiva utilização farmacêutica como inibidores de quinases
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20064669L (no) Dipeptidylpeptidaseinhibitorer
BRPI0516841A (pt) derivados bis-azaindóis, o respectivo preparado e a respectiva utilização farmacêutica como inibidores de quinases
CO5640117A2 (es) Derivados de 2,4-diamonopirimidina
BR0209334A (pt) Aminas n-aroil cìclicas
PE20070051A1 (es) Serin-amidas sustituidas con heteroaroilo
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20061406L (no) Organiske forbindelser
AR053405A1 (es) Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias
AR049951A1 (es) Derivados de ftalazina como inhibidores de parp
AR036107A1 (es) Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi
WO2002089800A3 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
BR0214809A (pt) Compostos de pirimidina
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
EA201070891A1 (ru) Замещенные гетероариламидные производные диазепинопиримидона
NO20061045L (no) Imidazolderivater
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter
RU2013157860A (ru) Производные бензотиазинтиона, способы их получения и применение
CO6160310A2 (es) Nuevos derivados imidazolonas su preparacion como medicamentos composiciones farmaceuticas utilizacion como inhibidores de proteinas quinasas principalmente cdc7

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 401/06, C07D 409/14, C07D 401/14, C07D 401/04, C07D 417/14, C07D 521/00, C07D 412/06, C07D 417/06, C07D 405/06, C07D 406/06, A61K 31/14, A61K 31/41, A61P 11/00, A61P 19/00

Ipc: C07D 401/06 (2011.01), C07D 409/14 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.